MBX Biosciences MBX
Management team
Background
Salomon (Sam) Azoulay, M.D., has served as our Chief Medical Officer since June 2024. Prior to joining MBX, Dr. Azoulay served as Chief Medical Officer at Sumitovant Biopharma Ltd., following Roivant Sciences Ltd.'s strategic spin-out of multiple portfolio companies to create an independent subsidiary of Sumitomo Pharma Co. Ltd., from January 2020 to July 2023. Dr. Azoulay previously served as Chief Medical Officer of Roivant from May 2018 to January 2020. Prior to Roivant, he served at Pfizer for nearly 20 years in positions of increasing responsibility, culminating in his position as Chief Medical Officer of Pfizer Essential Health from September 2013 to May 2018. Dr. Azoulay serves as an advisor to PharmStars' board of directors. Dr. Azoulay earned his M.D., with a specialty in cardiology, from the University of Paris VI. He also holds a D.E.S.S. in Business Administration and Management from the Sorbonne.
Background
On July 9, 2026, the Board appointed Steven Hoerter, the Company's current executive Chairman of the Board, as President and Chief Executive Officer and principal executive officer of the Company, effective as of July 13, 2026. Steven L. Hoerter has served on our board of directors since April 2025 and our executive chairperson since November 2025. Mr. Hoerter served as President, CEO and Director of Deciphera Pharmaceuticals, Inc. (Nasdaq: DCPH), a public commercial-stage biotechnology company, from March 2019 to June 2024, when Deciphera was acquired by ONO Pharmaceutical. From February 2016 to March 2019, Mr. Hoerter served as the Chief Commercial Officer of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a public biotechnology company. From August 2011 to March 2015, Mr. Hoerter served as Senior Vice President, Commercial at Clovis Oncology, Inc., a biotechnology company, and from March 2015 to February 2016, he served as Chief Commercial Officer. Mr. Hoerter has served on the board of directors of ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical-stage public biotechnology company, since August 2021. Mr. Hoerter has served on the board of directors of C4 Therapeutics (Nasdaq: CCCC), Inc., a clinical-stage public biopharmaceutical company, since November 2024. Mr. Hoerter previously served on the board of directors of Deciphera from May 2018 to June 2024, Constellation Pharmaceuticals, Inc. (formerly Nasdaq: CNST), a clinical-stage public biotechnology company, from September 2018 until its acquisition by MorphoSys AG (Nasdaq: MOR) in July 2021, and Ignyta, Inc.(formerly Nasdaq: RXDX), a publicly traded precision oncology company, from December 2016 until its acquisition by Roche Holding AG in February 2018. Mr. Hoerter holds a B.A. from Bucknell University, an M.B.A. from Tilburg University, and an M.S. in management from Purdue University.
Background
Patrick Heron has served on our board of directors since July 2020. He has been a Managing Partner of Frazier's Life Sciences team since August 1999. Prior to that, Mr. Heron helped develop McKinsey & Company's west coast biotechnology consulting practice. He currently serves on the boards of directors of Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) since November 2018, as well as chairman of the board of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) since January 2017. Mr. Heron previously served as a director of Imago Biosciences, Inc. (acquired by Merck & Co., Inc). from October 2014 to May 2022, Vaxcyte, Inc. (Nasdaq: PCVX) from April 2017 to September 2021, Passage Bio, Inc. (Nasdaq: PASG) from July 2018 to June 2021, HilleVax, Inc. (Nasdaq: HLVX) from March 2020 to August 2025 and Iterum Therapeutics plc (Nasdaq: ITRM) from August 2015 to March 2021. He has successfully partnered with entrepreneurs across a range of company types and stages, from early-stage drug discovery companies to $100M commercial-stage dermatology companies. He received his M.B.A. from Harvard Business School. He also holds a B.A. from the University of North Carolina at Chapel Hill, where he is a Phi Beta Kappa graduate and Morehead Scholar
Background
Tiba Aynechi, Ph.D., has served on our board of directors since November 2022. She has served as a General Partner of Norwest Venture Partners' healthcare team since December 2021 and previously, Dr. Aynechi served in various roles at Novo Holdings A/S, one of the top life sciences investment firms, from March 2010 to December 2021. Dr. Aynechi currently serves on the boards of directors of Avalyn Pharma, Inc., Engrail Therapeutics, Mosanna Therapeutics, Nuvig Therapeutics, Ray Therapeutics and Rezo Therapeutics. She has previously served on various public and private boards of directors including Spruce BioSciences (Nasdaq: SPRB) from May 2016 to December 2025, iRhythm Technologies, Inc. (Nasdaq: IRTC) from May 2014 to April 2017, Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) from October 2018 to August 2021, Nkarta, Inc. (Nasdaq: NKTX) from August 2015 to June 2022, Aristea Therapeutics, Inc. from August 2018 to December 2021 and MDLive Inc. from July 2018 to May 2021. Dr. Aynechi attended the University of California Irvine where she received a B.S. in Physics with a biomedical concentration. She also holds a Ph.D. in Biophysics from the University of California San Francisco, where she also did her Postdoctoral Fellowship. Dr. Aynechi is also a published author of scientific articles and book chapters in rational drug design.
Background
Ora Pescovitz, M.D., has served on our board of directors since April 2022. She has served as President of Oakland University since July 2017 and currently serves on the board of directors of Priority Health. Previously, Dr. Pescovitz served as Senior Vice President and U.S. Medical Leader for Lilly Biomedicines at Eli Lilly from October 2014 to June 2017. From April 2012 to February 2014, she served on the board of directors of Life Technologies Corporation (Nasdaq: Formerly LIFE, acquired by Thermo Fisher Scientific Inc. (NYSE: TMO)). From May 2009 to October 2014, she was the University of Michigan's first female Executive Vice President for Medical Affairs and Health System Chief Executive Officer. From 2004 to 2009, Dr. Pescovitz served as president and CEO of Riley Hospital for Children and previously served as executive associate dean for research affairs and interim vice president for research administration at Indiana University. Dr. Pescovitz is a nationally recognized pediatric endocrinologist and researcher who has published 190 papers and books, and received numerous awards for her research and teaching. Dr. Pescovitz earned her M.D. from the Northwestern University Feinberg School of Medicine, where she earned Distinguished Alumni Awards from both the Feinberg School of Medicine and Northwestern University. Dr. Pescovitz was elected to the National Academy of Medicine. We believe Dr. Pescovitz's qualifications to sit on our Board of Directors include her extensive academic, business and medical experience in the health care fields and her service on a public company board as well as several non-profit boards.
Background
Edward T. Mathers has served on our board of directors since July 2020. He has been a Partner at New Enterprise Associates, a venture capital firm, since August 2008. Mr. Mathers currently serves on the boards of directors of Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) since 2010, Synlogic, Inc. (Nasdaq: SYBX) since October 2012, Trevi Therapeutics, Inc. (Nasdaq:TRVI) since July 2017, OnKure Therapeutics, Inc. (formerly known as Reneo Pharmaceuticals, Inc.)(Nasdaq: OKUR) since December 2017, and Senti Biosciences, Inc. (Nasdaq: SNTI), as well as a number of private life sciences companies. Mr. Mathers previously served on the board of directors of Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) from November 2018 to September 2022, Akouos, Inc. (Nasdaq: Formerly AKUS, acquired by Eli Lilly) from October 2017 to December 2022, ObsEva SA (Nasdaq: OBSV) from November 2015 to June 2023, and Inozyme Pharma, Inc. (Nasdaq: INZY) from January 2017 to July 2025. Prior to joining New Enterprise Associates, Mr. Mathers served in various corporate development roles at MedImmune, Inc., a biotechnology company that was acquired by AstraZeneca PLC in 2007, culminating in the position of Executive Vice President, Corporate Development and Venture. In this role, he also led the company's venture capital subsidiary, MedImmune Ventures, Inc. Prior to that, Mr. Mathers was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems, Inc., a biopharmaceutical company, which is now known as Nektar Therapeutics, Inc. (Nasdaq: NKTR). Previously, for 15 years, Mr. Mathers was at Glaxo Wellcome, Inc., where he held sales and marketing positions of increasing responsibility. Mr. Mathers received a B.S. in chemistry from North Carolina State University.
Background
Steven Ryder, M.D., has served on our board of directors since January 2024. Dr.Ryder has served as the Chief Medical Officer of Rallybio Corporation (Nasdaq: RLYB) since January 2019. Previously, Dr. Ryder was the Chief Development Officer at Alexion Pharmaceuticals, Inc. (Nasdaq: Formerly ALXN, acquired by AstraZeneca PLC) from July 2013 to December 2018 and was the founding President of Astellas Pharma Global Development, Inc. from April 2008 to April 2013. Dr. Ryder also worked at Pfizer Inc. (Nasdaq: PFE) for 21 years where he held positions of increasing responsibility, including head of worldwide clinical development. Dr. Ryder has also held board positions at Reata Pharmaceuticals. Inc. (Nasdaq: Formerly RETA, acquired by Biogen Inc. (Nasdaq: BIIB)) from July 2022 to September 2023 and Levo Therapeutics, Inc. Dr. Ryder earned his Doctor of Medicine from the Icahn School of Medicine at Mount Sinai.
Background
Effective as of October 20, 2026, the board of directors of MBX Biosciences, Inc. , appointed Peter Radovich as a director of the Company.
Background
On July 9, 2026, the Board appointed John Smither, the Company's current interim Chief Financial Officer, as Chief Financial Officer and principal financial officer of the Company, effective as of July 13, 2026. John Smither has been appointed as the Company's Interim Chief Financial Officer, effective March 16, 2026. Mr. Smither, age 73, has over 40 years of experience in finance and accounting in the biotechnology industry. Mr. Smither previously served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) from May 2019 until March 2021, and again as Interim Chief Financial Officer from September 2023 to April 2024, and the Chief Financial Officer of Sienna Biopharmaceuticals, Inc. (Nasdaq: SNNA) from April 2018 until March 2019. Mr. Smither also served as the interim Chief Financial Officer at Kite Pharma (a Gilead Sciences, Inc. company) from October 2017 until April 2018 during its integration with Gilead. Mr. Smither presently serves on the board of directors of NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) as chair of its audit committee and Genelux Corporation (Nasdaq: GNLX) serving as chair of its compensation committee and as a member of its audit committee. Mr. Smither also served on the board of directors and audit committee chair of eFFECTOR Therapeutics, Inc. (Nasdaq: EFTR) from March 2018 to September 2023 and Applied Molecular Transport, Inc. (Nasdaq: AMTI) from January 2022 to December 2023. Mr. Smither also served as a member of the nomination and corporate governance committee of eFFECTOR Therapeutics and the compensation committee of Applied Molecular Transport. Mr. Smither previously served on the board of directors of Achaogen, Inc. and Principia Biopharma Inc and as the chair of their audit committees. Mr. Smither also has 15 years' experience as a practicing CPA (inactive), including time spent as an audit partner with Ernst & Young LLP.
Background
Ms. Laurie D. Stelzer, M.B.A. appointed as the Independent Director effective from January 20, 2026. Ms. Stelzer previously served as Chief Financial Officer of Kailera Therapeutics, a biotechnology company focused on GLP-1 therapeutics. She also currently serves on the boards of directors of Sionna Therapeutics, Inc., a clinical stage cystic fibrosis company; PMV Pharmaceuticals, Inc., a precision oncology company; and Spyre Therapeutics, Inc., a clinical stage biotechnology company focused on gastrointestinal and rheumatic diseases. For over 25 years, Ms. Stelzer has held leadership roles in finance, treasury, global accounting, business development, project management, and site operations for a range of biopharmaceutical companies including as Chief Financial Officer of Orna Therapeutics, Inc., Mirati Therapeutics, Inc., Arena Pharmaceuticals, Inc., and Halozyme Therapeutics, Inc. She also held senior management roles at Shire Plc and Amgen, Inc., and previously served on the boards of directors of Surface Oncology, Inc. and Longboard Pharmaceuticals. Ms. Stelzer earned a B.S. in Accounting from Arizona State University and an M.B.A. from University of California, Los Angeles, Anderson School of Management.
From SEC filings, via Futu. Compensation is total reported pay for the most recent fiscal year on file, not base salary alone.
No comments yet — be the first to weigh in on MBX.
Sign in to join the discussion.